Thursday, July 13, 2023 7:06:18 PM
The global PTSD treatment market size was valued at $16.0 billion in 2021 and is projected to reach $26.1 billion by 2031, growing at a compound annual growth rate (CAGR) of 4.9% (Vikita et al., 2022). With millions of people around the world suffering from PTSD, and no effective therapeutics currently available, Psychceutical's hope is that NeuroDirect ketamine could revolutionize the PTSD treatment market.
https://www.otcmarkets.com/stock/BWVI/news/First-Patient-Dosed-in-Psycheceuticals-Phase-I-Study-Exploring-Topical-Administration-of-Ketamine-to-Treat-PTSD?id=407406
$BWVI starting up clinical trials, bringing much needed medicine to the masses to combat the on going mental health crisis.
Recent BWVI News
- Form C/A - Offering Statement: [Amend] • Edgar (US Regulatory) • 11/01/2023 09:24:01 PM
- Will Shares of this Psycheceutical Pop on Dosing News? • AllPennyStocks.com • 07/13/2023 02:52:00 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM